Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, +8 more
PNAS (2008)
An eleven-amino-acid peptide reproducing the aqueous face of helix B of human erythropoietin retains the tissue-protective activity of EPO across stroke, retinal, renal, and peripheral-nerve injury models while remaining inactive at the homodimeric EPO receptor — the foundational design paper for ARA-290 / cibinetide.
This is the foundational primary characterization paper for the molecule that became ARA-290 / cibinetide, published in PNAS in 2008 by Michael Brines, Anthony Cerami, and a multi-institution collaboration spanning Italy, Portugal, Turkey, the United Kingdom, and the United States. The paper sets out a structural-pharmacology argument that erythropoietin (EPO)'s tissue-protective and anti-inflammatory activity is mediated by a receptor complex structurally and functionally distinct from the homodimeric EPO receptor that drives erythropoiesis — and then engineers a peptide that engages only the tissue-protective receptor.
The argument is built in three layers. First, the paper characterizes helix B of EPO as a region whose aqueous-facing residues are required for tissue-protective activity (neuroprotection in rat spinal cord cultures; reduction of infarct volume in rodent stroke models; suppression of diabetes-induced retinal edema; acceleration of recovery from sciatic-nerve trauma; protection against renal ischemia-reperfusion injury; acceleration of wound healing) but are not on the dimerization interface required for activation of the homodimeric (EPOR)₂ receptor that drives red-cell production. Second, the paper synthesizes an 11-amino-acid linear peptide reconstructing the aqueous face of helix B (the sequence that became pyroglutamate-EQLERALNSS in the developed form — although the development-grade pyroglutamate modification was added later for plasma stability) and shows that the peptide retains tissue-protective activity in the stroke and renal-ischemia models. Third, the paper demonstrates that the helix B surface peptide does not bind the homodimeric EPO receptor at any meaningful affinity and does not stimulate erythropoiesis in vitro or in vivo — the receptor decoupling that is the central design success.
The mechanistic frame the paper proposes — a heteromeric "tissue-protective receptor" composed of the EPO receptor and the common β-receptor (CD131) that is upregulated under tissue stress but not constitutively expressed at high levels — was elaborated subsequently by the same group as the innate repair receptor (IRR) framework, synthesized in Brines and Cerami, Mol Med 2012, 18:486–496. The 2008 PNAS paper is the load-bearing primary characterization that the entire ARA-290 / cibinetide program rests on, and is the principal entry for the IRR section of the peptide receptor pharmacology atlas.
The paper is preclinical in its entirety — no human data. The cross-injury-model breadth (stroke, retinal edema, peripheral nerve, renal, wound) is the paper's strongest evidence for the tissue-protective-receptor framing, but each individual model is reported at modest sample size, and the broader principle (that a single structural face of EPO mediates a single physiological function) is an inference from the model-level data rather than a directly observed receptor structure. The receptor identity itself — the EPOR + CD131 heterodimeric complex — is the central mechanistic claim, but the structural biology of the proposed heterodimer is less mature than for any of the conventional GPCRs on the peptide receptor pharmacology atlas; the molecular evidence for the heterodimer rests primarily on co-immunoprecipitation, gene-knockout phenotypes, and pharmacological cross-blockade rather than on crystallographic confirmation. The 2008 paper and the broader IRR program are concentrated in two laboratories (Brines/Cerami at Araim Pharmaceuticals and a small set of academic collaborators); independent replication of the receptor-decoupling architecture from non-affiliated structural-biology groups has been comparatively sparse. The molecule itself proceeded to a legitimate Phase II clinical-development program in sarcoidosis-associated small-fiber neuropathy (Heij 2012, Dahan 2013) and in diabetic peripheral neuropathy, but commercial development stalled in the late 2010s and no Phase III trial has been completed in any indication. The mechanism story remains elegant; the clinical-development depth that would confirm it at scale has not been produced.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.